ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

11 links0 made here, not in the record21 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05900206Trastuzumab DeruxtecanVersus Standard NeoadjuvantTreatment for HER2-positiveBreast CancerKarolinska University HospitalPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSTrastuzumab deruxtecanIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDocetaxelIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorCarboplatinIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPertuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorRibociclibIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorLetrozoleIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorEpirubicinIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorCyclophosphamideIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Trastuzumab deruxtecan

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Trastuzumab deruxtecan”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2Trastuzumab deruxtecanClaude Opus 5.5TestedCurrent
Nov 2DocetaxelClaude Opus 5.5ComparatorCurrent
Nov 2PaclitaxelClaude Opus 5.5ComparatorCurrent
Nov 2CarboplatinClaude Opus 5.5ComparatorCurrent
Nov 2TrastuzumabClaude Opus 5.5ComparatorCurrent
Nov 2PertuzumabClaude Opus 5.5ComparatorCurrent
Nov 2RibociclibClaude Opus 5.5ComparatorCurrent
Nov 2LetrozoleClaude Opus 5.5ComparatorCurrent
Nov 2EpirubicinClaude Opus 5.5ComparatorCurrent
Nov 2CyclophosphamideClaude Opus 5.5ComparatorCurrent
Nov 18Trastuzumab deruxtecanRule based · role ruleTestedAgrees
Nov 18DocetaxelRule based · role ruleComparatorAgrees
Nov 18PaclitaxelRule based · role ruleComparatorAgrees
Nov 18CarboplatinRule based · role ruleComparatorAgrees
Nov 18TrastuzumabRule based · role ruleComparatorAgrees
Nov 18PertuzumabRule based · role ruleComparatorAgrees
Nov 18RibociclibRule based · role ruleComparatorAgrees
Nov 18LetrozoleRule based · role ruleComparatorAgrees
Nov 18EpirubicinRule based · role ruleComparatorAgrees
Nov 18CyclophosphamideRule based · role ruleComparatorAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.